Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Tandem Diabetes Care (TNDM) Equity Average (2016 - 2025)

Tandem Diabetes Care's Equity Average history spans 12 years, with the latest figure at $144.1 million for Q4 2025.

  • For Q4 2025, Equity Average fell 42.47% year-over-year to $144.1 million; the TTM value through Dec 2025 reached $144.1 million, down 42.47%, while the annual FY2025 figure was $209.1 million, 27.48% down from the prior year.
  • Equity Average reached $144.1 million in Q4 2025 per TNDM's latest filing, up from $133.1 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $443.5 million in Q2 2022 to a low of $133.1 million in Q3 2025.
  • Average Equity Average over 5 years is $309.3 million, with a median of $325.7 million recorded in 2021.
  • Peak YoY movement for Equity Average: skyrocketed 69.02% in 2021, then tumbled 43.54% in 2025.
  • A 5-year view of Equity Average shows it stood at $411.4 million in 2021, then increased by 4.74% to $430.9 million in 2022, then dropped by 27.17% to $313.8 million in 2023, then fell by 20.21% to $250.4 million in 2024, then plummeted by 42.47% to $144.1 million in 2025.
  • Per Business Quant, the three most recent readings for TNDM's Equity Average are $144.1 million (Q4 2025), $133.1 million (Q3 2025), and $144.3 million (Q2 2025).